49
Participants
Start Date
March 20, 2018
Primary Completion Date
August 2, 2019
Study Completion Date
March 28, 2025
AG-120
Prior to surgery subjects will receive AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects without residual disease following surgery will have the option to receive treatment for up to a year, until disease progression or unacceptable toxicity, whichever occurs first. Subjects with residual disease following surgery will have the option to receive treatment, until disease progression or unacceptable toxicity.
AG881
Prior to surgery subjects will receive AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects without residual disease following surgery will have the option to receive treatment for up to a year, until disease progression or unacceptable toxicity, whichever occurs first. Subjects with residual disease following surgery will have the option to receive treatment, until disease progression or unacceptable toxicity.
United States, New York, New York
United States, North Carolina, Durham
United States, Texas, Dallas
United States, California, Los Angeles
United States, California, San Francisco
United States, Massachusetts, Boston
Institut de Recherches Internationales Servier
OTHER